JP Morgan Cazenove Maintains Shire PLC (LON:SHP)’s Overweight Rating; Nokomis Capital Upped Sequans Communications S A (SQNS) Stake

August 4, 2017 - By Maria Brooks

Today, JP Morgan Cazenove restate their Overweight rating on Shire PLC (LON:SHP)‘s stock in a note issued to clients and investors.

Nokomis Capital Llc increased Sequans Communications S A (SQNS) stake by 21.82% reported in 2016Q4 SEC filing. Nokomis Capital Llc acquired 972,616 shares as Sequans Communications S A (SQNS)’s stock rose 64.61%. The Nokomis Capital Llc holds 5.43M shares with $10.15M value, up from 4.46 million last quarter. Sequans Communications S A now has $221.74M valuation. The stock decreased 3.14% or $0.09 during the last trading session, reaching $2.78. About shares traded. Sequans Communications SA ADR (NYSE:SQNS) has risen 90.48% since August 4, 2016 and is uptrending. It has outperformed by 73.78% the S&P500.

Among 4 analysts covering Sequans Communications (NYSE:SQNS), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Sequans Communications has $600 highest and $3.20 lowest target. $4.93’s average target is 77.34% above currents $2.78 stock price. Sequans Communications had 8 analyst reports since February 8, 2016 according to SRatingsIntel. Needham maintained the stock with “Buy” rating in Tuesday, August 1 report. The firm has “Buy” rating given on Friday, March 18 by B. Riley & Co. The firm earned “Buy” rating on Tuesday, May 17 by Canaccord Genuity. On Monday, February 8 the stock rating was maintained by Needham with “Buy”. The stock has “Buy” rating by Northland Capital on Thursday, July 20. B. Riley & Co maintained Sequans Communications SA ADR (NYSE:SQNS) rating on Wednesday, August 2. B. Riley & Co has “Buy” rating and $5.5000 target.

Nokomis Capital Llc decreased Shutterfly Inc (NASDAQ:SFLY) stake by 207,601 shares to 101,844 valued at $5.11 million in 2016Q4. It also reduced Carbonite Inc (NASDAQ:CARB) stake by 1.03M shares and now owns 444,108 shares. B Riley Finl Inc was reduced too.

Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The company has market cap of 37.00 billion GBP. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It has a 85.87 P/E ratio. It focuses its development resources on projects in various therapeutic areas , including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.

Among 25 analysts covering Shire PLC (LON:SHP), 20 have Buy rating, 1 Sell and 4 Hold. Therefore 80% are positive. Shire PLC has GBX 7500 highest and GBX 214 lowest target. GBX 5389.65’s average target is 33.14% above currents GBX 4048 stock price. Shire PLC had 350 analyst reports since July 24, 2015 according to SRatingsIntel. As per Wednesday, June 15, the company rating was maintained by BNP Paribas. Liberum Capital maintained the shares of SHP in report on Wednesday, May 3 with “Buy” rating. The firm has “Buy” rating by Citigroup given on Wednesday, August 3. BNP Paribas maintained Shire PLC (LON:SHP) rating on Friday, October 30. BNP Paribas has “Neutral” rating and GBX 5700 target. As per Monday, February 27, the company rating was maintained by BNP Paribas. The stock of Shire PLC (LON:SHP) has “Outperform” rating given on Monday, November 2 by Bernstein. The stock has “Neutral” rating by Credit Suisse on Monday, October 26. On Friday, August 12 the stock rating was maintained by Shore Capital with “Buy”. The rating was maintained by BNP Paribas with “Outperform” on Tuesday, March 8. The company was maintained on Monday, March 7 by Bernstein.

About 665,837 shares traded. Shire PLC (LON:SHP) has 0.00% since August 4, 2016 and is . It has underperformed by 16.70% the S&P500.